This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Bone metabolism and osteoporosis and CKD

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Bone metabolism and osteoporosis :

  • not recommend that there should be routine measurement of calcium, phosphate, parathyroid hormone (PTH) and vitamin D levels in people with stage 1, 2, 3A or 3B CKD
  • measure serum calcium, phosphate and PTH concentrations in people with stage 4 or 5 CKD (GFR less than 30 ml/min/1.73 m2). Determine the subsequent frequency of testing by the measured values and the clinical circumstances. Where doubt exists seek specialist opinion
  • bisphosphonates should be offered (if indicated) for the prevention and treatment of osteoporosis in people with stage 1, 2, 3A or 3B CKD

  • Vitamin D supplements in the management of CKD-mineral and bone disorders
    • do not routinely offer vitamin D supplementation to manage or prevent CKD-mineral and bone disorders
    • offer colecalciferol or ergocalciferol to treat vitamin D deficiency in people with CKD and vitamin D deficiency
    • if vitamin D deficiency has been corrected and symptoms of CKD-mineral and bone disorders persist, offer alfacalcidol (1-alpha-hydroxycholecalciferol) or calcitriol (1-25-dihydroxycholecalciferol) to people with a GFR of less than 30 ml/min/1.73 m2 (GFR category G4 or G5)
    • monitor serum calcium and phosphate concentrations in people receiving alfacalcidol or calcitriol supplements

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.